Clinical Trials Logo

Inflammatory Response clinical trials

View clinical trials related to Inflammatory Response.

Filter by:

NCT ID: NCT05151094 Active, not recruiting - Covid19 Clinical Trials

Registry of Hospitalized Patients in University Hospital Dubrava Respiratory Center

COVID-19
Start date: April 1, 2021
Phase:
Study type: Observational [Patient Registry]

Aim of this project is to understand clinical features, clinical outcomes and efficacy and safety profiles of different therapies by analyzing a cohort of COVID-19 patients hospitalized and treated in a tertiary-level institution, University hospital Dubrava. Patients' clinical and laboratory characteristics, drug exposure and outcomes are obtained by analysis of written and electronical medical records.

NCT ID: NCT05126264 Completed - Pain Clinical Trials

Efficacy of Chronoterapy in Oral Surgery

ECOS
Start date: December 10, 2021
Phase: N/A
Study type: Interventional

Lower third molar extraction is one of the most common treatments in oral surgery practice. It is a treatment with inherent complications such as postoperative pain, swelling or trismus. In order to minimize disconfort after extraction, analgesic and anti-inflammatory medication is prescribed. Recently, it is seen that circadian rhythm may play an important role on drugs metabolism, modulating its effect depending on the moment of administration. The aim of the study is to analyze if dosage modification of a Non Steroideal Anti-Inflammatory (ibuprofen) affects on postoperative pain, swelling and open mouth limitation comparing to the normal dosage.

NCT ID: NCT05069311 Completed - Chronic Pain Clinical Trials

Effects of Multimodal Analgesia on Serum MCP-1, BDNF, and MiRNA-124 in Hysterectomy Surgery

Start date: October 15, 2021
Phase: N/A
Study type: Interventional

The inflammatory process is the main mechanism in the occurrence of acute postoperative pain. It is also the main risk for the development of acute pain into persistent pain. Inflammation occurs in the process of peripheral sensitization and central sensitization with various inflammatory mediators. Postoperatively, there will be proliferation and activation of microglia and astrocytes which will then activate inflammatory receptors and signaling cascades of neurotransmitters, cytokines, and chemokines. There has been a lot of clinical research evidence that multimodal analgesia can adequately treat acute pain and can prevent the development of acute postoperative pain into persistent pain and chronic postoperative pain, but the molecular mechanisms are not fully understood.

NCT ID: NCT05051306 Completed - Clinical trials for Inflammatory Response

Effects of Resistance Exercise on Metabolic Responses

Start date: February 18, 2021
Phase: N/A
Study type: Interventional

Healthy young adults will complete three trials in a randomized crossover counter-balanced order, including two different loads of resistance exercise and sedentary control. During each trial, blood samples will be collected. The investigators hypothesized that high-load and low-load resistance exercise exert similar metabolic responses.

NCT ID: NCT05042167 Completed - Aging Clinical Trials

The Effect of Resistance Exercise on Inflammation in Young and Older Adults

Start date: October 1, 2021
Phase: N/A
Study type: Interventional

Healthy young and older adults will complete two trials in a randomized crossover counter-balanced order, including resistance exercise and sedentary control. During each trial, blood samples will be collected. The investigators hypothesized that an acute bout of resistance exercise exert different inflammation responses in young and older adults.

NCT ID: NCT05039502 Completed - Clinical trials for Inflammatory Response

Releasing of Inflammatory Mediators During Retreatment of Root Canals

Start date: October 1, 2020
Phase: N/A
Study type: Interventional

Nonsurgical root canal retreatment may become essential when the initial endodontic treatment fails because of the persistent intracanal or extracanal infections.The aim of this thesis study is to evaluate the effect of ProTaper Universal Retreatment (PTUR), Reciproc blue and XP-endo Finisher R file systems, which are used in the removal of root canal filling materials during retreatment with different motion kinetics on the release of Substance P, Calcitonin Gene-Related Peptide (CGRP), IL-6 and IL-10 inflammatory mediators in the periapical region

NCT ID: NCT05033236 Completed - Clinical trials for Inflammatory Response

Platelets and Complement Activation in Coronary Artery Bypass Graft Surgery (CABG)

PAC
Start date: November 23, 2018
Phase:
Study type: Observational [Patient Registry]

Patients undergoing coronary artery bypass graft surgery (CABG) frequently exhibit postoperative bleeding complications which are still a major cause for morbidity and mortality. One major contributing factor is the loss of platelets and impaired platelet function. During cardiopulmonary bypass (CPB) blood comes in close contact with foreign surfaces which induces a series of reactions; especially the complement system as part of the innate immunity is highly activated. Due to the strong crosslink between complement system, platelet function and the plasmatic coagulation it is likely that complement activation during CPB has an impact on the overall process of clot formation. Besides the activation of the complement system there is growing evidence that the occurrence of mitochondrial DNA (mtDNA) during CPB might be related to further platelet activation . Activated platelets may enhance micro-thrombosis leading to organ failure and thereby contributing to postoperative morbidity. One major complication during and after CABG surgery is bleeding requiring transfusion and even reoperation in about 2%- 8% of patients. As bleeding complications increase patient morbidity and mortality, this study is designed to investigate the possible mechanisms of platelet loss during CABG. The hypothesis is that increased complement activation during CPB leads to platelet activation and loss of platelets. Further the degree of complement activation and levels of mtDNA might correlate with postoperative bleeding, transfusion requirements and clinical outcome.

NCT ID: NCT05020210 Enrolling by invitation - ARDS Clinical Trials

Effect of Early Treatment With Sivelestat Sodium in ARDS Patients

siv-ARDS
Start date: September 30, 2021
Phase:
Study type: Observational

This study is a multicenter, prospective, observational cohort study. The subjects were patients who developed ARDS within the preceding 72h. They were divided into 2 groups based on the use of sivelestat sodium which was determined by the physician in charge based on the condition of the patients: sivelestat sodium group and conventional treatment group. 560 patients were planned to be enrolled, with 280 patients in each group. In the sivelestat sodium group, patients were treated with sivelestat sodium within 72h of the diagnosis of ARDS. After 5 days of sivelestat treatment, sivelestat treatment should be stopped if the oxygenation index is greater than 300mmHg for at least 3 consecutive times; otherwise, sivelestat treatment should be continued until the oxygenation index is greater than 300mmHg for at least 3 consecutive times; if sivelestat treatment is continued until the 14th day, the drug should be stopped regardless of the oxygenation situation. Baseline data and Murray lung injury score, inflammatory markers, routine test results, duration of ECMO use/length of hospital stay/length of ICU stay were recorded at 1, 3,5, and 7 days after patients were enrolled, and patients were followed up on the 28th and 90th days.

NCT ID: NCT04990752 Recruiting - Clinical trials for Inflammatory Response

Effects of Ulinastatin on Inflammatory Response During ECMO Support

Uli-ECMO
Start date: July 26, 2021
Phase:
Study type: Observational [Patient Registry]

This study is a multicenter, prospective, observational cohort study. The subjects were patients who received ECMO support. According to whether ulinastatin is used in the treatment regimen (determined by the competent doctor according to the patient's condition), the patients were divided into the ulinastatin and control groups. In the ulinastatin group, ulinastatin was used for inflammation management and organ protection early before ECMO was started. Baseline data and inflammatory markers (CRP, IL-6, IL-10, TNF-α), capillary leakage markers, routine test results, duration of ECMO use/length of hospital stay/length of ICU stay were recorded at 1, 3, and 5 days after the start of ECMO support, and patients were followed up on the 28th and 90th days.

NCT ID: NCT04882020 Active, not recruiting - Inflammation Clinical Trials

Inflammation and Neurocognitive Damage Markers in Elderly People With Obstructive Sleep Apnea

Start date: August 21, 2019
Phase:
Study type: Observational

The aging process tends to promote an overall increase in inflammation compromising the immunologic system regulation, sleep/wakefulness pattern, and neurocognitive performance. In elders, there is an increase in repetitive arousals during sleep, secondary to breathing interruption by pharynx collapse, generating a transient reduction in oxygen delivery to the brain known as obstructive sleep apnea. This lack in oxygen supply results in an inflammatory process producing brain damage. Some substances present in the blood seem to be associated to neurocognitive damage, like S100β protein, cortisol, interleukin 1-β,6 and TNF-α. In the other way, a substance called brain-derived neurotrophic factor (BDNF) enhances cognitive function, and memory consolidation improvement.